A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease (EUCLID)

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Peripheral Artery Disease

Treatments: Drug: Clopidogrel; Drug: Ticagrelor

Study type: Interventional

Funder types: Industry

Identifiers

NCT01732822

D5135C00001

2011-004616-36 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.

Full description

A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Enrollment: 13,885 patients

Sex: All

Ages: 50 to 130 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and Female patients 50 years old or older Symptomatic peripheral artery disease

Exclusion criteria

• Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation
• Patients with known bleeding disorders
• Patients with a history of intracranial bleed
• Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

13,885 participants in 2 patient groups

Ticagrelor

Experimental group

Description:

Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets

Treatment:

Drug: Ticagrelor

Clopidogrel

Active Comparator group

Description:

Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets

Treatment:

Drug: Clopidogrel